Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

• Status: Not yet recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A PHASE 2a, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATING STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICALLY APPLIED BISPHOSPHOCIN NU-3 GEL TO CLINICALLY NONINFECTED CHRONIC DIABETIC FOOT ULCERS (cDFU)

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lakewood-Amedex Inc
• Collaborators: PrimeVigilance; Professional Education and Research Institute

Criteria

Inclusion Criteria:

1. Men and women at least 18 years of age and up to 80 years of age, inclusive.

2. Voluntary written consent, given before performance of any clinical investigation-related procedure, and with the understanding that consent may be withdrawn at any time without prejudice to future medical care.

3. Non-hospitalized ambulatory subjects suffering from diabetes mellitus, Type I or II per ADA criteria.

4. The target ulcer is classified as grade 1 ulcer according to a Wagner Scale. These ulcers are superficial, full-thickness ulcers limited to the dermis, not extending to the subcutis.

5. Target ulcer is between 2 and 10 cm2 post debridement at screening and baseline.

6. The target ulcer must be no higher than the ankle (on or below the malleolus (ankle bone) with ≥50% below the malleolus.

7. Presence of a persistent cDFU for at least 4 weeks and not more than 1 year that has failed to respond to standard of care.

8. Adequate vascular perfusion as evidenced by one of the following:

1. Dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 40 mmHg.

2. Ankle Branchial Index (ABI) between 0.7 and 1.3 within 3 months of Screening using the extremity with the target ulcer.

3. Arterial Doppler ultrasound evaluating for biphasic or triphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of > 0.6 is acceptable.

9. Subject has a caregiver who is able to attend baseline visit and apply wound treatment and study dressings for the study duration.

10. Subject completed protocol-defined standardized wound care during the Screening and Run-in periods leading up to Day 0.

11. Must meet one of the following criteria:

a. Female subjects of Non-Child-Bearing Potential defined as: i. Postmenopausal for at least 1 year, or surgically sterilized (i.e., hysterectomy or bilateral oophorectomy more than 3 months prior to Screening), or ii. Bilateral tubal ligation more than 6 months prior to Screening iii. Must have a negative serum β-hCG pregnancy test at screening and not be breastfeeding prior to being administered with the study drug.

b. Male subjects of Non-Childbearing Potential defined as those vasectomized subjects whose vasectomy was performed 6 months prior to Screening or those diagnosed as sterile by a physician.

c. Females and Males of Childbearing Potential who practice an acceptable method of contraception defined as the use of any form of hormonal contraceptive, a barrier method with spermicide, condoms, intrauterine device, or abstinence from sexual intercourse starting at least 60 days prior to Screening and continuing at least 30 days following the last treatment.

12. Subjects must be willing to undergo all clinical investigation-related procedures and attend all required visits.

Exclusion Criteria:

1. Ulceration with exposed tendon, capsule, or bone.

2. Suspicion of bone or joint infection by clinical or other criteria.

3. Unable or unwilling to utilize the standardized offloading RCW as required per protocol.

4. Target ulcer has decreased in area by ≥30% between Screening (V1) and Baseline (V3) visits.

5. Any subject that is currently on/requires oral, systemic or topical antibiotics, or is anticipated to require use during the course of the trial.

6. Any subject that has vascular compromise requiring surgical intervention or has undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. Any planned surgical procedures during the study participation.

7. Serum Creatinine level >3.0 mg/dL.

8. Hemoglobin A1c (HbA1c) >12%.

9. Aspartate Aminotransferase (AST, GOT) and/or Alanine Aminotransferase (ALT, GPT) >3x the upper limit of normal.

10. Acute active Charcot foot.

11. The target ulcer is within 3 cm of any other ulcer.

12. Any subject that would be unable to safely monitor the infection status at home, and return for scheduled visits.

13. History of immunosuppression or taking immunosuppressive agents including systemic corticosteroids, except stable daily doses of 5 mg/day or less for chronic conditions.

14. Any subject with a life expectancy ≤ 6 months.

15. Pregnancy, including a positive pregnancy test at Screening or Baseline, or lactation.

16. Use of investigational drugs within 28 days prior to screening.

17. History of concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol.

18. Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel.

19. Known or suspected active abuse of alcohol, narcotics, or non-prescription drugs.

20. Prior randomization in this clinical trial, or a previous Bisphosphocin study.